Amryt Pharma PLC (LON:AMYT) had its price objective reduced by Shore Capital from GBX 86 ($1.16) to GBX 70 ($0.94) in a note issued to investors on Thursday. The firm currently has a “house stock” rating on the stock. Shore Capital’s target price indicates a potential upside of 178.61% from the stock’s previous close.

Separately, Beaufort Securities reaffirmed a “speculative buy” rating and issued a GBX 62 ($0.84) price target on shares of Amryt Pharma PLC in a report on Wednesday, July 26th.

TRADEMARK VIOLATION NOTICE: “Shore Capital Cuts Amryt Pharma PLC (AMYT) Price Target to GBX 70” was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/21/amryt-pharma-plc-amyt-price-target-lowered-to-gbx-70-at-shore-capital.html.

About Amryt Pharma PLC

Amryt Pharma plc is a commercial-stage specialty pharmaceutical company focused on developing and delivering treatments for patients with rare and orphan diseases. The Company is building a diversified portfolio of proprietary drugs to help address some of rare and debilitating illnesses. The Company’s lead products include AP 101 and AP102.

Receive News & Ratings for Amryt Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amryt Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.